-transparent.png){kind=logo}
The in vivo chronic infusion of growth hormone releasing factor (GRF) results in a loss of the pituitary growth hormone (GH) response to GRF as well as in a substantial depletion of pituitary GH content. To evaluate if the loss in response is due to the down-regulation of GRF receptors the specific GRF binding capacity of pituitary homogenates prepared from rats infused with saline or GRF (1 or 15 micrograms/h for 24 h) was determined. The pituitary binding capacity of animals infused with GRF was significantly reduced as compared to animals infused with saline.
Related Publications
W B Wehrenberg, and
H Seifert, and
L M Bilezikjian, and
W Vale
January 1986,
Neuroendocrinology,
W B Wehrenberg, and
H Seifert, and
L M Bilezikjian, and
W Vale
April 1985,
Endocrinologia japonica,
W B Wehrenberg, and
H Seifert, and
L M Bilezikjian, and
W Vale
February 1988,
Neuroendocrinology,
W B Wehrenberg, and
H Seifert, and
L M Bilezikjian, and
W Vale
December 1984,
Endocrinologia japonica,
W B Wehrenberg, and
H Seifert, and
L M Bilezikjian, and
W Vale
January 1989,
Endocrinology,
W B Wehrenberg, and
H Seifert, and
L M Bilezikjian, and
W Vale
May 1988,
Fertility and sterility,
W B Wehrenberg, and
H Seifert, and
L M Bilezikjian, and
W Vale
April 1992,
Domestic animal endocrinology,
W B Wehrenberg, and
H Seifert, and
L M Bilezikjian, and
W Vale
November 2018,
Proceedings of the National Academy of Sciences of the United States of America,
W B Wehrenberg, and
H Seifert, and
L M Bilezikjian, and
W Vale
September 1985,
Acta endocrinologica,
W B Wehrenberg, and
H Seifert, and
L M Bilezikjian, and
W Vale
January 1983,
Nature,
